SAN FRANCISCO - Positive findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study cohorts on the potential benefit of various molecularly targeted drugs in patients with advanced colorectal cancer will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January 23-25, 2020 at the Moscone West Building in San Francisco, California.

The TAPUR Study is the first clinical trial conducted by ASCO and aims to describe the performance (both safety and efficacy) of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Read more about how the TAPUR Study illustrates the power of personalized treatment in colorectal cancer in ASCO Daily News or contact the Media Team to speak with an expert in gastrointestinal cancers about the studies below.

Abstract 122:

Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.

Abstract 132:

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.

Abstract 133:

Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.